Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential.

Simple item page
dc.contributor.authorAhmad, Zahooren_US
dc.contributor.authorPandey, Rajeshen_US
dc.contributor.authorSharma, Sadhnaen_US
dc.contributor.authorKhuller, G Ken_US
dc.date.accessioned2006-07-10en_US
dc.date.accessioned2009-05-27T10:15:51Z
dc.date.available2006-07-10en_US
dc.date.available2009-05-27T10:15:51Z
dc.date.issued2006-07-10en_US
dc.description.abstractBACKGROUND: Reduction in the dosing frequency of antituberculosis drugs (ATDs) by applying drug delivery technology has the potential to improve the patient compliance in tuberculosis (TB). Alginate (a natural polymer) based nanoparticulate delivery system was developed for frontline ATDs (rifampicin, isoniazid, pyrazinamide and ethambutol). METHODS: Alginate nanoparticles were prepared by the controlled cation induced gelification method and administered orally to mice. The drug levels were analysed by high performance liquid chromatography (HPLC) in plasma/tissues. The therapeutic efficacy was evaluated in M. tuberculosis H37Rv infected mice. RESULTS: High drug encapsulation efficiency was achieved in alginate nanoparticles, ranging from 70%-90%. A single oral dose resulted in therapeutic drug concentrations in the plasma for 7-11 days and in the organs (lungs, liver and spleen) for 15 days. In comparison to free drugs (which were cleared from plasma/organs within 12-24 h), there was a significant enhancement in the relative bioavailability of encapsulated drugs. In TB-infected mice three oral doses of the formulation spaced 15 days apart resulted in complete bacterial clearance from the organs, compared to 45 conventional doses of orally administered free drugs. CONCLUSIONS: Alginate nanoparticles appear to have the potential for intermittent therapy of TB.en_US
dc.description.affiliationDepartment of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India.en_US
dc.identifier.citationAhmad Z, Pandey R, Sharma S, Khuller GK. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. The Indian Journal of Chest Diseases & Allied Sciences. 2006 Jul-Sep; 48(3): 171-6en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/29531
dc.language.isoengen_US
dc.source.urihttps://medind.nic.in/iae/iaem.shtmlen_US
dc.subject.meshAlginates --pharmacokineticsen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAntitubercular Agents --administration & dosageen_US
dc.subject.meshBiocompatible Materials --pharmacokineticsen_US
dc.subject.meshDrug Delivery Systemsen_US
dc.subject.meshEthambutol --administration & dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshGlucuronic Acid --pharmacokineticsen_US
dc.subject.meshHexuronic Acids --pharmacokineticsen_US
dc.subject.meshIsoniazid --administration & dosageen_US
dc.subject.meshMaleen_US
dc.subject.meshMiceen_US
dc.subject.meshNanoparticles --therapeutic useen_US
dc.subject.meshPyrazinamide --administration & dosageen_US
dc.subject.meshRifampin --administration & dosageen_US
dc.subject.meshTuberculosis --drug therapyen_US
dc.titleAlginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential.en_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Indian Journal of Chest Diseases & Allied Sciences